Vir Biotechnology to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference SAN FRANCISCO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company will participate in a fireside chat at the Morgan Stanley 20th Annual Global...

Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2022 Financial Results on August 4, 2022 SAN FRANCISCO, July 21, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the second quarter...

Vir Biotechnology Reminds Stockholders of 2022 Annual General Meeting Details SAN FRANCISCO, May 18, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2022 Annual General Meeting of Stockholders on Friday, May 20,...

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2022 Financial Results – $1.2 billion of sotrovimab collaboration revenue recognized in the first quarter – – More than $2.5 billion in cash, cash equivalents, investments and collaboration receivables at the end of the...